Literature DB >> 20600325

Interactions between immunoglobulin G molecules.

Roald Nezlin1.   

Abstract

Immune globulin preparations such as intravenous immunoglobulin (IVIG) and monoclonal antibodies are widely used in clinics as effective therapeutic agents for the treatment of a number of autoimmune diseases, cancer, inflammations and other pathologies. Significant amounts of IgG aggregates have been found in the highly concentrated solutions of therapeutic immune proteins. The IgG self-aggregation that appears especially after prolonged storage increases the immunogenicity of the preparations and also modifies their physical properties, first of all producing the high viscosity. The attractive IgG-IgG interactions pose a significant problem for the clinical usage of the immune proteins. During last decades intensive studies of the IgG self-association were performed. The presence of IgG dimers was demonstrated in pooled preparations. These complexes are the result of idiotype-anti-idiotype interactions. In concentrated solutions of immune globulins and monoclonal antibodies self-associated IgG molecules formed a network, increasing the viscosity. The forces responsible for the IgG association are characteristic of the protein-protein interactions in general. The amino acid residues of the Fab and Fc portions participate in the IgG-IgG contacts. Recently contact residues were modified by the site-directed mutagenesis in order to decrease the formation of the IgG self-aggregates. The mutant IgG antibodies were characterized by enhanced stability as compared with the non-modified antibody molecules. Peptic pFc' fragment and the C(H)3 domain were shown to be capable of interacting with Fc regions, thus preventing IgG aggregation. In perspective both approaches could improve the formulation of immune globulin preparations. Removal of IgG aggregates could be achieved by chromatography on hydroxyapatite. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20600325     DOI: 10.1016/j.imlet.2010.06.006

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  7 in total

1.  The limitations of an exclusively colloidal view of protein solution hydrodynamics and rheology.

Authors:  Prasad S Sarangapani; Steven D Hudson; Kalman B Migler; Jai A Pathak
Journal:  Biophys J       Date:  2013-11-19       Impact factor: 4.033

2.  Behavior of monoclonal antibodies: relation between the second virial coefficient (B (2)) at low concentrations and aggregation propensity and viscosity at high concentrations.

Authors:  Shuntaro Saito; Jun Hasegawa; Naoki Kobayashi; Naoyuki Kishi; Susumu Uchiyama; Kiichi Fukui
Journal:  Pharm Res       Date:  2011-08-19       Impact factor: 4.200

3.  Anticomplementary activity of horse IgG and F(ab')2 antivenoms.

Authors:  Carla Cristina Squaiella-Baptistão; José Roberto Marcelino; Luiz Eduardo Ribeiro da Cunha; José María Gutiérrez; Denise V Tambourgi
Journal:  Am J Trop Med Hyg       Date:  2014-01-20       Impact factor: 2.345

Review 4.  Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity.

Authors:  Karin A van Schie; Gerrit-Jan Wolbink; Theo Rispens
Journal:  MAbs       Date:  2015       Impact factor: 5.857

5.  Coformulation of Broadly Neutralizing Antibodies 3BNC117 and PGT121: Analytical Challenges During Preformulation Characterization and Storage Stability Studies.

Authors:  Ashaben Patel; Vineet Gupta; John Hickey; Nancy S Nightlinger; Richard S Rogers; Christine Siska; Sangeeta B Joshi; Michael S Seaman; David B Volkin; Bruce A Kerwin
Journal:  J Pharm Sci       Date:  2018-09-01       Impact factor: 3.534

6.  The impact of forced degradation conditions on mAb dimer formation and subsequent influence on aggregation propensity.

Authors:  Michael J Knight; Léontine Floret; Nisha Patel; John O'Hara; Elizabeth Rodriguez
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 6.440

7.  Antibody therapy can enhance AngiotensinII-induced myocardial fibrosis.

Authors:  Nicole L Rosin; Alison J Gareau; Devin Betsch; Alec Falkenham; Mryanda J Sopel; Timothy Dg Lee; Jean-Francois Légaré
Journal:  Fibrogenesis Tissue Repair       Date:  2014-04-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.